News and Events – Chimeric Therapeutics

Press Releases

January 2023

Follow Up Period Completed for 3rd Cohort in CHM1101 Trial

January 2023

1st Patient Dosed in CHM0201 + Vactosertib Trial

December 2022

Completion of Dosing in 3rd Dose Cohort in CHM 1101 (CLTX CAR T) Clinical Trial

November 2022

Licence Agreement with CWRU (Supplementary Announcement)

November 2022

Exclusive Licence Agreement with CWRU for CORE-NK Platform

November 2022

Sponsored Research Agreement to Advance CORE-NK Portfolio

September 2022

Dr Stephaine Astrow Appointed VP Translational Sciences

August 2022

Patent Received in Japan for CLTX CAR Technology

July 2022

Cell Therapy Industry Leader Appointed Chief Medical Officer

July 2022

Appointment of Cassandra Harrison to VP Clinical Operations and Data Management

June 2022

Chimeric Licenses Viral Vector Technology from University of Pennsylvania for CDH17 CAR T Program

June 2022

First Ever Phase 1B Trial of NK Cells with IL-2 and VACTOSERTIB

June 2022

Chimeric Completes Key Manufacturing Milestone Supporting Expansion of Clinical Program

June 2022

Chimeric enters A$30M Equity Placement Agreement with L1 Capital

Events and Presentations

October 2022

On The Bid – Stockhead video series – CAR T therapy edition featuring CHM CEO Jenn Chow

September 2022

ASX Small and Mid Cap Conference – Jennifer Chow CEO 23 Sep 2022

November 2021

CHM 1101 (CLTX CAR T) Presents Positive Initial Phase 1 Clinical Data

November 2021

CHM 1101 (CLTX CAR T) Phase 1 Initial Data Release Presentation

October 2021

CEO Jennifer Chow’s presentation at AusBiotech Conference 2021

October 2021

CHM Virtual User Meeting Guide 2021

Recent Media Coverage

May 2022

CEO Jennifer Chow talks about expanding the company’s cancer trials

February 2022

CEO Jennifer Chow Presents at the FNN Investor Event Feb 2022

February 2022

Paul Hopper speaks to Matt Birney from Bulls N’ Bears

February 2022

CEO Jennifer Chow interviewed on Stockhead Feb 2022

February 2022

CEO Jennifer Chow interviewed on RAAS Feb 2022

February 2022

CEO Jennifer Chow interviewed on Proactive Investors Feb 2022

February 2022

CEO Jennifer Chow interviewed on Financial News Network Feb 2022

December 2021

CEO Interview on Positive Initial Phase 1 Clinical Data

November 2021

Rat’s Rant – The Godzilla Edition Chimeric Therapeutics (small cap CAR T bio tech play)

September 2021

Boardroom Media

Media Resources

“How Dose CAR T Work” Infographic

Background to CLTX CAR T

Background to CDH17 CAR T